Skip to Content
Merck
All Photos(1)

Key Documents

AB5664P

Sigma-Aldrich

Anti-Neurite Outgrowth Inhibitor A Antibody

Chemicon®, from rabbit

Synonym(s):

Nogo-A

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human, rat, mouse

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
western blot: suitable

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... RTN4(57142)

Specificity

Recognizes rat Neurite Outgrowth Inhibitor Protein A (Nogo-A). The immunogen shows no significant sequence homology with the alternatively spliced shorter forms Nogo-B or Nogo-C.

Immunogen

An 18 amino acid peptide sequence in the middle region of the putative extracellular domain of rat Nogo-A (Chen et al. 2000; GrandPre et al. 2000; Goldberg & Barres 2000; Prinijha et al. 2000; Tessier-Lavigne & Goodman 2000; Nagase et al. 1998).

The immunogen peptide is highly conserved in mouse (94%) and human (83%) Nogo-A.

Application

Anti-Neurite Outgrowth Inhibitor A Antibody is an antibody against Neurite Outgrowth Inhibitor A for use in ELISA & WB.
Research Category
Neuroscience
Research Sub Category
Neurochemistry & Neurotrophins

Growth Cones & Axon Guidance
Western blot: 1-10 μg/mL using ECL. The calculated molecular weight of Nogo-A is approximately 135 kDa. However a molecular weight of approximately 180 kDa has been reported for full length Nogo-A (Chen et al. 2000; GrandPre et al. 2000; Goldberg & Barres 2000; Prinijha et al. 2000; Tessier-Lavigne & Goodman 2000; Nagase et al. 1998).

ELISA: 1:10,000-1:100,000 using 50-100 ng control peptide (Catalog Number AG348) per well.

Optimal working dilutions must be determined by the end user.

Linkage

Replaces: AB5888

Physical form

Affinity purified immunoglobulin. Liquid in PBS containing 0.1% BSA.

Storage and Stability

Maintain at -20°C in undiluted aliquots for up to 6 months afet date of receipt. Avoid repeated freeze/thaw cycles.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hong Zhao et al.
Molecular medicine reports, 24(6) (2021-10-14)
Axon regeneration after lesions to the central nervous system (CNS) is largely limited by the presence of growth inhibitory molecules expressed in myelin. Nogo‑A is a principal inhibitor of neurite outgrowth, and blocking the activity of Nogo‑A can induce axonal
Jian-Qiang Lu et al.
Journal of neuropathology and experimental neurology, 72(12), 1135-1144 (2013-11-15)
Activation of signal transducer and activator of transcription 3 (STAT3) by phosphorylation is thought to mediate anti-inflammatory responses to CNS injury. Several studies have reported an increase in phosphorylated STAT3 (pSTAT3) in peripheral T cells and monocytes from patients with
Manuela Cerina et al.
Brain structure & function, 223(7), 3091-3106 (2018-05-11)
Alterations in cortical cellular organization, network functionality, as well as cognitive and locomotor deficits were recently suggested to be pathological hallmarks in multiple sclerosis and corresponding animal models as they might occur following demyelination. To investigate functional changes following demyelination
Daniela Klotz et al.
International journal of molecular sciences, 20(7) (2019-04-04)
The demyelinating canine distemper virus (CDV)-leukoencephalitis represents a translational animal model for multiple sclerosis. The present study investigated the expression of type I interferon (IFN-I) pathway members in CDV-induced cerebellar lesions to gain an insight into their role in lesion
Agnes E Nystad et al.
Journal of neuroimmunology, 339, 577091-577091 (2019-11-19)
Fingolimod is used to treat patients with relapsing-remitting multiple sclerosis; it crosses the blood-brain barrier and modulates sphingosine-1-phosphate receptors (S1PRs). Oligodendrocytes, astrocytes, microglia, and neuronal cells express S1PRs, and fingolimod could potentially improve remyelination and be neuroprotective. We used the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service